|Year : 2001 | Volume
| Issue : 2 | Page : 81-90
Role of Cytokines in experimental and clinical uveitis
Vijay K Singh, Geeta Rai, Shyam S Agarwal
Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India,
Vijay K Singh
Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
| Abstract|| |
Uveitis is a major cause of visual impairment. Experimental autoimmune uveitis mimics the clinical conditions of posterior uveitis in many ways. T-cells (particularly CD4[+] helper-T-cells) have been shown to play an important role in pathogenesis of experimental and clinical uveitis. Based on the pattern of cytokine they secrete, CD4[+] helper cells have been divided into Thl and Th2 subsets. Various Thl and Th2 cytokines appear to be involved in the pathogenesis and/or recovery from uveitis. This article discusses in detail the uveitopathogenic and therapeutic potential of Thl and Th2 cytokines in experimental and clinical uveitis.
Keywords: Autoimmunity, experimental autoimmune uveitis, human uveitis, Th1 and Th2 cytokines
|How to cite this article:|
Singh VK, Rai G, Agarwal SS. Role of Cytokines in experimental and clinical uveitis. Indian J Ophthalmol 2001;49:81-90
|How to cite this URL:|
Singh VK, Rai G, Agarwal SS. Role of Cytokines in experimental and clinical uveitis. Indian J Ophthalmol [serial online] 2001 [cited 2013 May 21];49:81-90. Available from: http://www.ijo.in/text.asp?2001/49/2/81/22654
Indian J Ophthalmol 2001;49:81-90
The immune system has both non-specific and specific components. Non-specific or innate immunity is the basic resistance to disease that an individual is born with. Innate defence mechanisms provide the first line of host defence and the innate system is fully functional before infectious agents enter the body. In contrast, the acquired immune system (specific component) is activated only after a pathogen has entered the-body. A developed immune system is capable of distinguishing between self and non-self, raising an appropriate response to eliminate or neutralize the foreign molecule and tolerate the self. When the immune response is directed against the self, it is known as autoimmunity. Earlier it was believed that all self-reactive lymphocytes are eliminated during development, and failure to eliminate them leads to autoimmune reaction. Later experimental evidence revealed that not all self-reactive lymphocytes are deleted during maturation. Instead, normal healthy individuals have been shown to produce mature self-reactive lymphocytes. Since; the presence of self-reactive lymphocytes does not inevitably result in autoimmune reaction; their activity must be regulated in normal individuals through clonal anergy or clonal suppression. A breakdown in this regulation leads to activation of self-reactive clones of T and B-cells, resulting in cellular or humoral autoimmunity. Autoimmune responses are usually sustained and persistent, leading to long-term tissue damage presumably because the self antigens that drive the response can only be removed from the system by destroying the cells that produce them.
Uveitis is an intraocular inflammation involving primarily the uveal tract, i.e. the iris, ciliary body and choroid. Autoimmunity plays an important role in certain uveitic entities. It is known to cause a variable degree of visual loss depending on the type and severity of uveitis. Morbidity is characterised by an inflammatory attack on the uvea and the neuroretina. Infection, autoimmune disease, trauma, and malignancy can induce uveitis. The disease may be of infectious or autoimmune aetiology. The latter includes sympathetic ophthalmia, Vogt-Koyanagi-Harada syndrome More Details, Behcet's disease, birdshot retinochoroidopathy, and sarcoiduveitis. The possible role of retinal antigens in the aetiopathogenesis of a subset of human uveitis is supported by the observation that many patients with uveitis show lymphoproliferative response to human and bovine retinal antigens.[6-10]
| Experimental Autoimmune Uveitis as Animal Model for Human Posterior Uveitis|| |
Our understanding of the immunopathogenic mechanisms of posterior uveitis has been benefited enormously by the development of an animal model of uveitis, experimental autoimmune uveitis (EAU).[11-13]EAU closely resembles human uveitic conditions of suspected autoimmune aetiology and serves as a model for these sight-threatening diseases. Subsequently it has helped in elucidating the basic mechanisms involved in pathogenesis and in development of new therapeutic approaches.
EAU is predominantly a T-cell mediated intraocular inflammatory disease induced in susceptible species/ strains of animals by active immunization with ocular-specific proteins (or peptides derived from them).[14-18]The two major uveitogenic retinal proteins are S-antigen and interphotoreceptor retinoid-binding protein (IRBP). [11, 12, 18, 19] EAU is induced either by active immunization or by adoptive transfer. In active immunization the retinal antigens or their peptides along with mycobacterium emulsified in complete Freund's adjuvant are injected into the footpad of the animal followed by an intravenous injection of Bordetella pertussis. In adoptive transfer, lymphocytes from an animal with EAU are transferred to a naive recipient. The naive recipient develops EAU in 3 - 4 days after the transfer as compared to 12 to 14 days in case of active immunization in rats [Figure - 1]. The disease can also be transmitted to naïve syngeneic animals by injection of Major Histocompatibility Complex (MHC) II-restricted T-cell lines specific to retinal antigens. [20, 21] Several examples of molecular mimicry between retinal S-antigen fragment and microbial proteins or self-protein (human leukocyte antigen) have also been demonstrated.[22-25] Microbial peptide or peptide derived from human leukocyte antigen has been shown to induce EAU in susceptible animals. The experimental animal used in the majority of early studies on EAU is the Lewis rat, an inbred strain that is highly susceptible to EAU induced by all known uveitogenic antigens. [14, 26, 27]Taken together with unique anatomic sequestration of the vertebrate eye, EAU is a useful model of organ-specific autoimmunity mediated by T - lymphocytes, [28, 29]useful for studying many aspects of immunobiology and immunomodulation. [30, 31] Interestingly, Rao raises a question whether the S-antigen induced uveitis model represents human uveitis or retinal autoimmunity. Thus additional studies are required to fully understand the complex workings of the ocular immune system.
| Th1 and Th2 cytokines|| |
In 1986, Mosmann and colleagues revolutionized the field of immunology by dividing T-helper (Th) cells into two distinct populations with contrasting and cross-regulating cytokine profiles. Studies on leishmania infection in mice were instrumental in establishing functional relevance of these subsets of Th cells. Th1 cells produce interferon-γ (IFN-γ), interleukin-2 (IL-2) and tumour necrosis factorβ
); promote production of opsonizing and complement-fixing antibodies, macrophage activation, antibody-dependent cell cytotoxicity and delayed type hypersensitivity (DTH) reactions. In contrast, Th2 cells produce several interleukins (IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13); provide help for humoral immune response, particularly of the IgE type and mucosal immunity through facilitation of IgA synthesis. Furthermore, Th1 cells are considered to give rise to phagocyte-dependent and Th2 cells phagocyte-independent host response. The factors responsible for the polarization of the specific immune response into a predominant Th1 and Th2 profile have been extensively investigated. Strong evidence suggests that Th1 and Th2 cells develop from the same Th-cell precursor under the influence of environmental and genetic factors acting at their level of antigen presentation (Figure 2).
From mice, the concept of Th1 and Th2 response has extended to rats and humans, and has been applied to infectious diseases, cancer, transplantation, neonatal tolerance, immunodeficiency, autoimmunity, allergy, virology and more. Sufficient evidence has now accumulated to demonstrate the role of Th1 and Th2 cytokines in induction and control of several experimental as well as human autoimmune diseases.Evidence has accumulated from animal models to indicate that Th1-type lymphokines are involved in the genesis of various organ-specific autoimmune diseases, such as uveitis, autoimmune thyroiditis, allergic encephalomyelitis, multiple sclerosis, arthritis or insulin-dependent diabetes mellitus. Studies in humans also favour a Th1-type of lymphokine profile in target organs of patients with organ-specific autoimmunity. In contrast, Th2-cell predominance was found in skin of patients with chronic graft-versus host disease, progressive systemic sclerosis, systemic lupus erythematosus and allergic diseases. The concept of Th1 and Th2 cells not only allows one to explain different types of protective immune responses but also provides a basis for pathogenesis of several immunological diseases.
| Anterior Chamber Associated Immune Deviation (ACAID) and Cytokines|| |
Injection of antigen into the anterior chamber of the eye induces suppression of antigen-specific DTH called ACAID. It has been shown that two types of splenic regulatory cells impair the induction and expression phase of DTH, and are involved in ACAID. These cells mediate the effect through a cytokine. D'Orazio and Niederkorn have shown that ACAID evokes antigen-specific, systemic down regulation of Th1 responses to antigen inoculated into the anterior chamber of the eye. IFN-γ production is suppressed in ACAID. It has been reported that IFN-γ when injected intracamerally robbed the eye of immune privilege and prevented ACAID induction. [40, 41]
IL-12 production is also suppressed in-ACAID.TNF has been associated with prevention of ACAID induction when injected intracamerally. The cytokine profile of the infiltrating T-cells in the eye with ACAID induction showed higher expression of IL-4 and-IL-10.Kosiewicz et al has shown that spleen and lymph node cells of mice produced significant amounts of IL-4 when ACAID was induced in their eyes. A high level of IL-10 secretion is associated with ACAID induction. The role of IL-10 in ACAID was confirmed in IL-10 knockout mice. Anterior chamber injection of ovalbumin into IL-10 knockout mice elicited normal DTH responses and not ACAID. CD4[+] spleen cells from hosts primed in the anterior chamber with ACAID-inducing antigens developed normal DTH responses. This is suggestive of the proposition that immune privilege in the activation of the Th2 population is due to the selective activation of Th2 population. In ACAID, the immune response is directed away from Th1 pathway towards a Th2-like pathway in which DTH is suppressed.
| Th1 and Th2 Cytokines in EAU|| |
The pathogenesis of EAU is mediated through the Th1 response. The susceptibility to EAU is characterised by conversion of early Th0 (CD4[+] T cells expressing cytokines of both types) or Th2-like response to Th1-type, whereas resistance is associated with Th2-type response. Various Th1 and Th2 cytokines have been implicated in pathogenesis/recovery/resistance of EAU (Table 1). There is also a suggestion that regulatory influences other than skewing the response toward the Th2 pathway may be equally effective in conferring genetic resistance to EAU.
| Th1 Cytokines|| |
Th1 cells induce several cytotoxic cells and inflammatory reactions mediated by IL-2, IFN-γ, TNF-β
and IL-12; and are responsible for cell-mediated inflammatory reactions, DTH and tissue injury in autoimmune diseases. Th1-dominant immune responses are associated with inflammation and tissue injury. Th1 responses predominate in organ-specific autoimmune diseases. Cytokines have also been shown to play important role in aetiopathogenesis of EAU and human uveitis.
| IFN-γ|| |
IFN-γ plays a central role in host defence, in both innate and acquired immunity. Aberrant expression of MHC class II proteins in ocular tissues has also been observed in uveitis. As the autoreactive T-cells that mediate autoimmune pathology are predominantly Th1 lymphocytes and produce copious amounts of IFN-γ, it was proposed that expression of MHC class II molecules on target cells by IFN-γ may be a risk factor for developing organ-specific autoimmune diseases. In EAU as well as in uveitis patients, IFN-γ mRNA and protein have been detected in the inflammed eye. The expression of IFN- γ mRNA is temporally correlated with the onset of uveitis suggesting involvement of IFN-γ in induction and pathogenesis of uveitis.[47-50] Egwuagu and colleagues recently generated transgenic rats (rats produced by injection of foreign cloned DNA in a fertilized egg where it integrates into the chromosomal DNA for birth of transgenic pups) with targeted expression of IFN-γ in the eye and examined whether constitutive ocular expression of IFN-γ would influence the course of EAU. They found that onset of EAU in rats is markedly accelerated and exacerbated by IFN-γ.
In the mouse model, depletion of systemic IFN-γ has been shown to result in exacerbation of EAU.Mouse strains that are resistant to EAU induction, were converted to susceptible phenotype by peripheral administration of anti-IFN-γ antibody showing that endogenously produced IFN-γ at systemic levels acts to downregulate EAU in mice. Jones et al have demonstrated, using IFN-γ knockout mice (mice having a disrupted gene with loss of function in place of normal gene), that IFN-γ is not required for priming of pathogenic T-cells or for effecting retinal damage and photoreceptor loss typical of EAU, and a grossly similar disease is caused in the knockout mice by a deviant effector response (elevated IL-5, IL-6, IL-10, lymphotoxin but not IL-4). These results therefore suggest a protective effect of IFN-γ in EAU and imply potential benefits of IFN-γ therapy in the treatment of uveitis. Thus it is obvious that IFN-γ plays an important role in pathogenesis of EAU. The different effect of IFN- γ in mice and rat models is due to systemic and local effects, respectively. Systemic effects are exerted on the components of the immune system, and are different from local effects that are exerted on the target tissues.
| IL-2|| |
IL-2 is produced by helper Thl cells. Major targets of IL-2 action are T-cells, B-cells and NK cells. The primary function of IL-2 is to cause proliferation and activation of T-and B-cells. It has been suggested that development, severity and subsidence of EAU are dependent on the level of IL-2. [49, 56, 57] Anti-IL-2 receptor antibody has been found effective in controlling EAU. The phenomenon of oral tolerance has been established in a number of experimental models of autoimmune disease. Two major mechanisms that have been proposed to mediate oral tolerance are anergy and active suppression. Rizzo et alhave shown that IL-2 can dramatically enhance oral tolerance from disease induced by IRBP in BIO A mice.
| IL-12|| |
IL-12 is the central cytokine in development and progression of tissue specific autoimmunity. It is produced by professional antigen presenting cells such as dendritic cells, skin Langerhans cells and B-cells. The dependence of Th-driven autoimmune disease models on IL-12 is explained by the role of this cytokine in driving differentiation of naive T-cells to Thl pathway.Yokoi et al demonstrated that anti-IL-12 treatment at the time of priming with IRBP not only prevented development of EAU and of pathogenic Thl cells, but also induced suppressive Th2 cells that protected animals from further challenge by the same antigen. Anti IL-12 treatment did not impair in vivo splenocyte proliferation significantly, but production of IL-2 and IFN-γ was greatly reduced while IL-4 and IL-5 was increased. Tarrant et al have shown that IL-12 deficient mice were unable to develop EAU after immunization with a maximal disease inducing regimen, and their antigen specific responses to the uveitogenic antigen were Th2 like. However, they were able to develop EAU when infused with their own primed cells that had been incubated with antigen in the presence of IL-12. It is therefore concluded that the resistance of IL-12 knockout mice to EAU involves an inability to develop a pathogenic Thl response to the uveitogen and that endogenous IL-12 is required for pathogenesis of EAU. Furthermore, Tarrant et al demonstrated that administration of IL-12 aborts development of EAU in IRBP-immunized mice by curtailing development of uveitogenic effector T cells.
| TNF-α|| |
The TNF family consists of three members, i.e., TNF-α
(also known as lymphotoxin a; LT-α
). The major source of TNF-α
is activated monocytes/ macrophages. Ex-vivo analysis of cytokines produced in response to the immunising antigen showed an enhancement in the level of TNF-α
following IL-4 treatment. Dick et al have shown that inhibiting TNF a activity prevents tissue destruction without inhibiting retinal T-cell infiltration in EAU. Neutralizing TNF a activity has been shown to suppress Thl effector mechanisms protecting against target organ damage.
IL-18 and TNF-β
have not been investigated in EAU or human uveitis.
| Th2 Cytokines|| |
Th2 cytokines include IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13, and are associated with help to B-cell antibody production. The activation of Th2 cells generally protects the organism from a Thl-dependent autoimmune disease. A brief account of the involvement of Th2 cytokines, in EAU is given below.
| IL-4|| |
IL-4 is a small soluble glycoprotein secreted by activated T-lymphocytes, basophils and mast cells. In the case of EAU, IL-4 has been shown to play an important role and enhance the level of IFN-γ production. Uveitopathogenic effector T-cells of mice have a Thl-like phenotype. Antigen-specific uveitogenic cells do not produce IL-4 but addition of IL-4 enhances production of IFN-γ. Furthermore, Kezuka et al have shown that priming of mice with IRBP peptide 518-529 causes a shift from Thl to Th2 (IL-4 and IL-10) dominated immune response, thereby playing a pivotal role in prevention of IRBP-mediated EAU. Rizzo et al have also suggested that administration of IL-4 is required to shift response towards a non-pathogenic Th2 pathway.
A higher level of IL-4 has been reported in eyes with EAU. An elevated level of IL-4 has also been reported in orally or orchidically (intratesticular) tolerized mice with retinal antigen. Caspi et al have suggested that susceptibility to EAU is connected with a Thl-dominant response, but resistance can involve either a "null" response (Thl-low/Th2-low) or a Th2-dominant response.
| IL-6|| |
IL-6 has a wide variety of activities on immune cell function, replication and differentiation. It is produced mainly by monocytes, T-lymphocytes and fibroblasts. It induces B-cell differentiation, activates T-cells and induces myelomonocytic differentiation as well. IL-6 produces uveitis if administered intraocularly.Elevated levels of IL-6 producing cells have been reported in uveitic eyes of mice. In addition, primed lymph node cells produced higher levels of IL-6 in response to IRBP. It has also been suggested that at onset of EAU, the ocular microenvironment loses its immunosuppressive properties due to local production of IL-6.
| IL-10|| |
IL-10 was originally characterized as a cytokine-synthesis inhibitory factor because of its capacity to inhibit cytokine production by mouse Thl cells, monocytes, macrophages and B-cells. It is currently regarded as a potential therapeutic agent for inflammatory diseases involving Thl-type response because of its ability to downregulate Thl cells and macrophages. IL-10 is an important cytokine for aetiopathogenesis of EAU. The disease is negatively regulated by IL-10. Increase in IL-10 mRNA expression during late phase of EAU may reflect a role in disease resolution. Endogenous IL-10 limits expression of EAU and may play a role in natural resolution of disease.The data suggests that exogenous IL-10 may be useful in therapeutic control of autoimmune uveitis. IL-10 along with IL-4 is required to induce oral tolerance against-EAU.
The antidepressant and phosphodiesterase inhibitor, rolipram, enhances IL-10 production by monocytes/ macrophage but its protective effect against EAU is independent of IL-10.
| IL-13|| |
IL-13 is a cytokine that is produced by a subset of T-cells and dendritic cells. IL-13 inhibits production of proinflammatory cytokines by activated monocytes, induces B-cell proliferation, IgE production and expression of certain adhesion molecules on endothelial cells. Roberge et al has shown that uveitis induced in monkeys by immunisation with human retinal S-antigen can be treated by IL-13. They have shown that IL-13 inhibited intraocular inflammation and produced an increase in circulating polymorphonuclear neutrophils and a decrease in lymphocytes. Thus administration of IL-13 appears to be a promising modality of treatment of severe uveitis.
IL-5 and IL-9 have not been investigated in EAU or human uveitis.
| Th1 and Th2 Cytokines and Human Uveitis|| |
Various Th1 and Th2 cytokines have been investigated in ocular fluids (vitreous and aqueous humour), serum samples and supernatant of stimulated peripheral blood mononuclear cells (PBMC) of different categories of uveitis patients. Number of cytokine-producing cells in ocular tissues of uveitis patients have also been enumerated and compared with healthy controls. Chan and Li have reported T-cell infiltration in other non-infectious inflammatory diseases like ligneous conjunctivitis, pars planitis, sarcoid uveitis, sympathetic ophthalmia and Vogt-Koyanagi-Harada syndrome. T-cell infiltration has been documented mainly in Behcet's disease and scleritis. Numerous CD4[+] T cells and Thl cytokine mRNAs have been detected in eyes with active sympathetic ophthalmia and Behcet's disease. This demonstrates that the infiltrating T-lymphocytes have Thl function and promote cellular immune response in the eye. Behcet's disease is the most studied of the various types of uveitis, in relation to cytokines.
Excessively elevated IL-2 levels may enhance the development and recurrence of human uveitis. IL-2 has been detected in ocular fluid of uveitis patients. [50, 76] The number of IL-2 producing cells in PBMC of Behcet's disease patients with active uveitis was significantly higher than inactive cases and controls. Elevated levels of soluble IL-2R has been reported in the serum of patients with juvenile chronic arthritis associated with uveitis. High levels of soluble IL-2R have been reported in the serum of patients with active Behcet's disease. This suggests that the disease activates the immune system. IFN-γ has also been reported in the ocular tissues of uveitis patients. [50, 68]
el-Shabrawai et al found statistically significant differences in IL-12 levels in vitreous/aqueous humor of patients with uveitis (active > inactive > control). This further supports the general hypothesis that uveitis is a Thl-mediated disease where IL-12 plays a pivotal role in the initiation and maintenance of intraocular inflammation. High levels of IL-12 in vitreous and /or aqueous humor of patients with uveitis also suggest that susceptibility to ocular autoimmunity may be related to genetic predisposition to an elevated Thl response.
Ongkosuwito et al failed to detect IL-4 in ocular fluid samples from patients with uveitis. Raziuddin et al have reported enhanced level of IL-4 in the culture supernatant of stimulated PBMC of uveitis patients. Furthermore, Sugi et al did not find any difference in the number of IL-4 producing cells in PBMC of active and inactive uveitis patients. Elevated levels of IL-6 have been reported in aqueous humor [76, 82, 83] and vitreous [76, 84] of patients with uveitis. Investigators have failed to establish a correlation between IL-6 level in ocular fluids and clinical severity or aetiology of the disease. Human retinal pigment epithelium (RPE) has also been shown to produce IL-6. Unstimulated RPE produced small amounts of IL-6, but on stimulation with IL-1, IL-6 production was markedly upregulated. Thus RPE may be the source of this cytokine in ocular inflammatory states. Furthermore, in comparison to controls, elevated levels of IL-6 were found in aqueous humour as compared to serum of patients with uveitis.The soluble IL-6 receptor levels in aqueous humour were 2-10 times higher than IL-6 levels. In serum samples, soluble IL-6 receptor levels were 1000 times higher than the corresponding IL-6 values. These results confirm the role of IL-6 in intraocular inflammation and give new information regarding the presence of its soluble receptor in inflamed eyes. Low levels of soluble IL-6R in aqueous humour compared to the levels in serum suggest the presence of active regulatory mechanisms that require further investigation.
Elevated levels of IL-10 have been reported in ocular fluids (aqueous and vitreous) of uveitis patients [50, 79, 80]. Raziuddin et al have shown high levels of IL-13 in the PBMC of patients with Behcet's disease.
| Future Directions|| |
A coherent view of the role of Th1 and Th2 cytokines in uveitis is emerging as a result of studies both in human and experimental animals. Cytokines have been demonstrated in various ocular fluids and tissues obtained from uveitis patients, and have been shown to induce disease in experimental animals upon intraocular injections. Several unique features of the immunology of the eye, such as immunosuppression associated with ACAID, may also be due to various cytokines.
The balance between Th1 and Th2 types of immune responses plays a crucial role in determining the outcome of a uveitopathogenic challenge. [45, 61, 87, 88] While susceptible strains of mice and rats consistently exhibit a dominant Th1 response to the uveitopathogenic antigen at the time of disease expression, resistant strains exhibit a low Th1, or an overt Th2 response at the same time. Although there have been significant advances in our understanding of the process leading to development of polarised Th1 and Th2 effectors at the single cell level, the evolution of a Th1 or Th2 responses in vivo remains poorly documented. Several Th1/Th2 cytokines have been shown to be involved in the pathogenesis of uveitis, among which IFN-γ and IL-12 are of particular importance. Usually activation of Th2 cells is a protection against Th1-dependent autoimmune diseases. The anti-inflammatory Th2 cytokines IL-4 and IL-10 seem to be promising candidates for therapy in human uveitis.
Oral tolerance in EAU may occur by anergy/depletion or by suppression, depending on the feeding regimen. Tolerance involving putative regulatory cells appears to require production of both IL-4 and IL-10 cytokines. It would be worthwhile to explore therapeutic feeding regimens involving administration of IL-4 and IL-10. In brief, an understanding of the role of cytokines in inflammatory eye diseases can help us develop therapies to abrogate the effects of important mediators of inflammatory responses. An antibody directed against the T-cell activated (Tac) portion of the IL-2 receptor is under clinical trial for treatment of uveitis.
| Acknowledgements|| |
Financial assistance from Indian Council of Medical Research towards research on the subject is gratefully acknowledged. GR is a PhD student of SGPGI. The laboratory infrastructure was provided by a JICA grant-in-aid to the SGPGI project.
| References|| |
|1.||Kuby J. Immunology. New York, NY, USA: W. H. Freeman and Company; 4[th] ed; 2000. |
|2.||Adelstein S, Pritchard-Briscoe H, Anderson TA, Crosbie J, Gammon G, Loblay RH, et al. Induction of self-tolerance in T-cells but not B cells of transgenic mice expressing little self antigen. Science 1991; 251:1223-25. [PUBMED] [FULLTEXT]|
|3.||Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis:Fundamentals and clinical practice. St Louis, USA: Mosby; 2[nd] ed;1996. |
|4.||Nussenblatt RB, Tabbara KF. Posterior uveitis: Diagnosis and Management. In: Tabbara KF, Nussenblatt RB, editors. Autoimmune Diseases. Boston: Butterworth-Heineann, 1994. p 85-114. |
|5.||Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-88. [PUBMED] [FULLTEXT]|
|6.||Nussenblatt RB, Gery I, Ballintine EJ, Wacker WB. Cellular immune responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol 1980;89:173-79. [PUBMED] [FULLTEXT]|
|7.||Hirose S, Donoso LA, Shinohara T, Palestine AG, Nussenblatt RB Gery I. Lymphocyte responses to peptide M and to retinal S-antigen in uveitis patients. Jpn J Ophthalmol 1990;34:298-305. |
|8.||de Smet MD, Yamamoto JH, Mochizuki M, Gery I, Singh VK, Shinohara T, et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol 1990;110:135-42. [PUBMED] [FULLTEXT]|
|9.||Nityanand S, Singh VK, Shinohara T, Paul AK, Singh V, Agarwal PK, et al. Cellular immune response of patients with uveitis to peptide M, a retinal S-antigen fragment. J Clin Immunol 1993;13:352-58. [PUBMED] [FULLTEXT]|
|10.||Rajasingh J, Singh VK, Singh V, Sharma K, Agarwal SS. Cellular immune response to retinal S-antigen and interphotoreceptor retinoid binding protein fragments in idiopathic human uveitis. Indian J Med Res 1996;103:222-26. [PUBMED] [FULLTEXT]|
|11.||Wacker WB, Lipton MM. Experimental allergic uveitis: I. Homologous retina as uveitogenic antigen. Nature 1965;206:253-54. [PUBMED] [FULLTEXT]|
|12.||Wacker WB, Lipton MM. Experimental allergic uveitis. I. Production in the guinea-pigs and rabbit by immunization with retina in adjuvant. J Immunol 1968;101:151-56. [PUBMED] [FULLTEXT]|
|13.||Faure JP. Autoimmunity and the retina. Curr Top Eye Res 1980;2:215-302. [PUBMED] [FULLTEXT]|
|14.||Gery I, Wiggert B, Redmond TM, Kuwabara T, Crawford MA, Vistica BP, et al. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid binding protein. Invest Ophthalmol Vis Sci 1986;27:1296-300. [PUBMED] [FULLTEXT]|
|15.||Singh VK, Yamaki K, Donoso LA, Shinohara T. S-antigen: experimental autoimmune uveitis induced in guinea pigs with two synthetic peptides. Curr Eye Res 1988;7:87-92. [PUBMED] [FULLTEXT]|
|16.||Donoso LA, Merryman CF, Shinohara T, Sery TW, Smith A. S-antigen: Experimental autoimmune uveitis following immunization with small synthetic peptide. Arch Ophthalmol 1987;105:838-40. |
|17.||de Smet MD, Bitar G, Roberge FG, Gery I, Nussenblatt RB. Human S-antigen: Presence of multiple immunogenic and immunopathogenic sites in the Lewis rat. J Autoimmun 1993;6:587-99. [PUBMED] [FULLTEXT]|
|18.||Inoue H, Takeuchi M, Tanaka T, Ando S, Usui M, Taguchi O. Analysis of the uveitopathogenic determinant in repeat structure of retinal interphotoreceptor retinoid-binding protein (IRBP). Clin Exp Immunol 1994;97:219-25. [PUBMED] [FULLTEXT]|
|19.||Hirose S, Kuwabara T, Nussenblatt RB, Wiggert B, Redmond TM, Gery I. Uveitis induced in primates by interphotoreceptor retinoid binding protein. Arch Ophthalmol 1986;104:1698-702. [PUBMED] [FULLTEXT]|
|20.||Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats: Immunopathogenic mechanisms and histologic features. Invest Ophthalmol Vis Sci 1985;26:1-9. |
|21.||Gery I, Streilein JW. Autoimmunity in the eye and its regulation. Curr Opin Immunol 1994;6:938-45. [PUBMED] [FULLTEXT]|
|22.||Singh VK, Yamaki K, Abe T, Shinohara T. Molecular mimicry between uveitopathogenic site of retinal S-antigen and Escherichia coli protein: Induction of experimental autoimmune uveitis and lymphocyte cross reaction. Cell Immunol 1989;122:262-73. |
|23.||Singh VK, Yamaki K, Donoso LA, Shinohara T. Molecular mimicry: Yeast histone H3 induced experimental autoimmune uveitis. J Immunol 1989;142:1512-17. [PUBMED] [FULLTEXT]|
|24.||Singh VK, Kalra HK, Yamaki K, Abe T, Donoso LA, Shinohara T. Molecular mimicry between the uveitopathogenic site of retinal S-antigen and viral peptides. Induction of experimental autoimmune uveitis in Lewis rats. J Immunol 1990;144:1282-87. [PUBMED] [FULLTEXT]|
|25.||Singh VK, Nagaraju K. Experimental autoimmune uveitis: Molecular mimicry and oral tolerance. Immunol Res 1996;15:323-46. [PUBMED] [FULLTEXT]|
|26.||Wacker WB, Donoso LA, Kalso w CM, Yankeelov JA Jr, Organisciak DT. Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol 1977;119:1949-58. |
|27.||Broekhuyse RM, Winkens HJ, Kuhlmann ED. Induction of experimental autoimmune uveoretinitis and pinealitis by IRBP. Comparison to uveoretinitis induced by S-antigen and opsin. Curr Eye Res 1986;5:231-40. [PUBMED] [FULLTEXT]|
|28.||Nussenblatt RB, Kuwabara T, de Monasterio FM, Wacker WB. S-antigen uveitis in primates. A new model for human disease. Arch Ophthalmol 1981;99:1090-92. [PUBMED] [FULLTEXT]|
|29.||Singh VK, Biswas S, Anand R, Agarwal SS. Experimental autoimmune uveitis as animal model for human posterior uveitis. Ind J Med Res 1998;107:53-67. [PUBMED] [FULLTEXT]|
|30.||Nussenblatt RB. Current research in immunomodulation of uveitis. Invest Ophthalmol Vis Sci 1998;39(S):215. |
|31.||Singh VK, Biswas S, Rai G, Agarwal SS. Immunomodulation in human and experimental uveitis: Recent advances. Ind J Ophthalmol 1999;47:65-77. |
|32.||Rao NA. Do the experimental models represents human uveitis or retinal autoimmunity? Ind J Ophthalmol 1999;47:62-63. |
|33.||Mosmann TR, Cherwinski II, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57. |
|34.||Romagnani S. The Thl/Th2 paradigm. Immunol Today 1997;18:263-66. [PUBMED] [FULLTEXT]|
|35.||Fowell D, McKnight AJ, Powrie F, Dyke R, Mason D. Subsets of CD4[+] T cells and their roles in the induction and prevention of autoimmunity. Immunol Rev 1991;123:37-64. [PUBMED] [FULLTEXT]|
|36.||Romagnani S. Human Th1 and Th2 subsets: Doubt no more. Immunol Today 1991;12:256-57. |
|37.||Singh VK, Mehrotra S, Agarwal SS. The Paradigm of Th1 and Th2 Cytokines: Its relevance to autoimmunity and allergy. Immunol Res 1999;20:147-61. |
|38.||Kosiewicz MM, Alard P, Streilein JW. Alterations in cytokine production following intraocular injection of solubile protein antigen: impairment of IFN-γ and induction of TGF-β |
|39.|| and IL-4 production. J Immunol 1998;161:5382-90. |
|40.||D'Orazio TJ, Niederkorn JY. The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response. Eur J Immunol 1998;28:1544-53. |
|41.||Okamoto S, Streilein JW. Role of inflammatory cytokines in induction of anterior chamber-associated immune deviation. Ocul Immunol Inflamm 1998;6:1-11. |
|42.||Geiger K, Sarvetnick N. Local productionof IFN-γ abrogates the intraocular immune privilege in transgenic mice and prevents the induction of ACAID. J Immunol 1994;153:5239-46. |
|43.||Takahashi M, Ishimaru N, Yanagi K, Saegusa K, Haneji N, Shiota H, Hayashi Y. Requirement for splenic CD4[+] T cells in the immune privilege of the anterior chamber of the eye. Clin Exp Immunol 999;116:231-37. |
|44.||D'Orazio LT, Niederkorn JY. A novel role for TGF-β |
|45.|| and IL-10 in the induction of immune privilege. J Immunol 1998;160:2089-98. |
|46.||Sun B, Sun S, Chan CC, Wiggert B, Caspi RR. Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease susceptible and towards type 2 in a disease resistant genotype. Int Immunol 1999;11:1307-12. |
|47.||Sun B, Rizzo LV, Sun SH, Chan CC, Wiggert B, Wilder RL, et al. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper 2-like response. J Immunol 1997;159:1004-11. |
|48.||Feldmann M, Londei M, Buchan G. Interferons and autoimmunity. Interferon 1987;9:75-90. |
|49.||Hooks JJ, Chan CC, Detrick B. Identification of the lymphokines, interferon-γ and interleukin-2, in inflammatory eye diseases. Invest Ophthalmol Vis Sci 1988;29:1444-51. |
|50.||Caspi RR, Sun B, Agarwal RK, Silver PB, Rizzo LV, Chan CC, et al. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye 1997;11:209-12. |
|51.||Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:111-20. |
|52.||Ongkosuwito JV, Feron EJ, van Doornik CE, Vander Lelij A, Hoyng CB, La Heij EC, et al. Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis Sci 1998;39:2659-65. |
|53.||Egwuagu CE, Sztein J, Mahdi RM, Li W, Chan C C, Smith JA, et al. IFN-γ increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J Immunol 1999;162:510-17. |
|54.||Caspi RR, Parsa C, Chan CC, Grubbs BG, Bahmanyar S, Heremans H, et al. Neutralization of endogenous Interferon-a exacerbates experimental autoimmune uveoretinitis in the mouse model. Invest Ophthalmol Vis Sci 1991;32(S):790. |
|55.||Caspi RR, Chan CC, Grubbs BG, Silver PB, Wiggert B, Parsa CF, et al. Endogenous systemic IFN-ã has a protective role against ocular autoimmunity in mice. J Immunol 1994;152:890-99. |
|56.||Jones L S, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, et al. IFN-γ deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997;158:5997-6005. |
|57.||Hamel CP, Detrick B, Hooks JJ. Evaluation of I a expression in rat ocular tissues following inoculation with interferon-γ._Exp Eye Res 1990;50:173-82. |
|58.||Takeuchi M, Kezuka T, Inoue H, Sakai J, Usui M, Takahashi T, et al. Suppression of spontaneous uveitoretinitis by non immunopathogenic peptide immunization. Eur J Immunol 1998;28:1578-86. |
|59.||Okada AA, Keino H, Fukai T, Sakai J, Usui M, Mizuguchi J. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:215-26. |
|60.||Rizzo LV, Miller-Rivero NE, Chan CC, Wiggert B, Nussenblatt RB, Caspi RR. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 1994;94:1668-72. |
|61.||Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol 1998;88:4-13. |
|62.||Yokoi H, Kato K, Kezuka T, Sakai J, Usui M, Yagita H, et al. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur J Immunol 1997;27:641-66. |
|63.||Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for the induction and expression of experimental autoimmune uveitis. J Immunol 1998;161:122-27. |
|64.||Tarrant TK, Silver PB, Wahlstein JL, Rizzo LV, Chan CC, Wiggert B, et al. Interleukin-12 protects from a T helper type 1 mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med 1999;189:219-30. |
|65.||Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. Autoimmunity 1998;11:255-64. |
|66.||Mosmann TR, Schumacher JH, Street NF, Budd R, O'Garra A, Fong TA, et al. Diversity of cytokine synthesis and function of mouse CD4[+] T cells. Immunol Rev 1991,123:209-229. |
|67.||Kezuka T, Sakai J, Yokoi H, Takeuchi M, Okada A, Taguchi O, et al. Peptide-mediated suppression of experimental autoimmune uveoretinitis in mice:development of peptide vaccine. Int Immunol 1996;8:1229-35. |
|68.||Rizzo LV, Xu H, Chan CC, Wiggert B, Caspi RR. IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 1998;10:807-14. |
|69.||Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, et al. IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol 1999;162:2613-22. |
|70.||Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 1992;4:1-5. |
|71.||Ohta K, Wiggert B, Yamagami S, Taylor AW, Streilein JW. Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 2000;164:1185-92. |
|72.||Pretolani M, Goldman M. IL-10; a potential therapy for allergic inflammation? Immunol Today 1997;18:277-80. |
|73.||Li Q, Sun B, Dastgheib K, Chan CC. Suppressive effect of transforming growth factor β |
|74.||1 on the recurrence of experimental melanin induced uveitis:upregulation of ocular interleukin-10. Clin Immunol Immunopathol 1996;81:55-61. |
|75.||Xu H, Strassmann G, Chan CC, Rizzo LV, Silver PB, Wiggert B, et al. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU:protection is independent of IL-10 inducing activity. Invest Ophthalmol Vis Sci 1999;40:942-50. |
|76.||de Vries JE, Zurawski G. Immunoregulatory properties of IL-13:its potential role in atopic disease. Int Arch Allergy Immunol 1995;106:175-79. |
|77.||Roberge FG, de Smet MD, Benichou J, Kriete MF, Raber J, Hakimi J. Treatment of uveitis with recombinant human interleukin-13. Br J Ophthalmol 1998;82:1195-98. |
|78.||Chan CC, Li Q. Immunopathology of uveitis. Br J Ophthalmol 1998;82:91-96. |
|79.||Franks WA, Limb GA, Stanford MR, Oglivie J, Wolstencraft RA, Chignell AH, et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992;11:187-91. |
|80.||Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2 and interferon gamma producing T cells in patients with active Behcet's disease. Invest Ophthalmol Vis Sci 1998;39:996-1004. |
|81.||Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S. Cytokines in Behcet's disease. J Rheumatol 1996;23:321-22. |
|82.||el-Shabrawi Y, Livir-Rallatos C, Christen W, Baltatzis S, Foster CS. High levels of interleukin-12 in the aqueous humor and vitreous of patients with uveitis. Ophthalmology 1998;105:1659-63. |
|83.||Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behcet's disease. Altered Thl/Th2 cell cytokine pattern. J Rheumatol 1998;25:329-33. |
|84.||Sugi N, Nakazawa M, Nakamura S, Minami M, Ohno S. Analysis of the profile of CD4[+] cells in Behcet's disease. Nippon Ganka Gakkai Zasshi 1997;101:335-40. |
|85.||Feys J, Emond JP, Salvanet-Bouccara A, Dublanchet A. Interleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis. J Fr Ophthalmol 1994;17:634-39. |
|86.||Murray PI, Hoekzema R, Van Haren MA, de Hon FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci 1990;31:917-20. |
|87.||De Boer JH, Van Haren MA, de Vries-Knoppert WA, Baarsma GS, de Jong PV, Postema FJ, et al. Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 1992;11:181-86. |
|88.||Benson MT, Sheperd L, Rees RC, Rennie IG. Production of Interleukin-6 by human retinal pigment epithelium in vitro and its regulation by other cytokines. Curr Eye Res 1992;11:173-79. |
|89.||Petrinovic-Doresic J, Mazuran R, Henc-Petrinovic L, Kuzmanovic B, Jovicic A. Interleukin-6 and its soluble receptors are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm 1999;7:75-84. |
|90.||Caspi RR. Thl and Th2 lymphocytes in experimental autoimmune uveoretinitis. In Nussenblat RB, Whitcup SM, Caspi RR, Gery I. editors. Advances in Ocular Immunology ( Proc. 6[th] Int. Symp. On the Immunology and Immunopathology of the Eye). Amsterdam: Elsevier Science;1994. p 55. |
|91.||Caspi RR, Silver PB, Chan CC, Sun B, Agarwal RK, Wells J, et al. Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Thl response. J Immunol 1996;157:2668-75. |
|92.||Kronin V, Winkel K, Suss G, Kelso A, Heath W, Kirberg J, et al. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J Immunol 1996;157:3819-27. |
|93.||Caspi RR, Stiff LR, Morawetz R, Miller-Rivero NE, Chan CC, Wiggert B, et al. Cytokine dependent modulation of oral tolerance in a murine model of autoimmune uveitis. |
|94.||Ann NY Acad Sci 1996;778:315-24. |
[Figure - 1], [Figure - 2]
[Table - 1]
|This article has been cited by|
||Serum PEDF levels are decreased in a spontaneous animal model for human autoimmune uveitis
| ||Zipplies, J.K., Hauck, S.M., Schoeffmann, S., Amann, B., Stangassinger, M., Uefflng, M., Deeg, C.A. |
| ||Journal of Proteome Research. 2009; 8(2): 992-998 |